

István Bitter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924152/publications.pdf>

Version: 2024-02-01

114
papers

9,771
citations

81900

39
h-index

37204

96
g-index

117
all docs

117
docs citations

117
times ranked

12770
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
2	Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	3
3	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
4	ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	4
5	Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 645-659.	2.1	4
6	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	10.4	156
7	Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. <i>Schizophrenia Bulletin</i> , 2022, 48, 1228-1240.	4.3	2
8	Primary Negative Symptoms: Refining the Research Target. <i>Schizophrenia Bulletin</i> , 2021, 47, 1207-1210.	4.3	3
9	Atypical resting-state gamma band trajectory in adult attention deficit/hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2021, 128, 1239-1248.	2.8	3
10	A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?. <i>Translational Psychiatry</i> , 2021, 11, 510.	4.8	13
11	Assessment and Treatment of Negative Symptoms in Schizophrenia – A Regional Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 820801.	2.6	8
12	Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 71-82.	3.2	16
13	Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling – an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 28.	1.5	0
14	Impaired early information processing in adult ADHD: a high-density ERP study. <i>BMC Psychiatry</i> , 2020, 20, 292.	2.6	11
15	Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. <i>Trials</i> , 2020, 21, 161.	1.6	21
16	Multivariate patterns of EEG microstate parameters and their role in the discrimination of patients with schizophrenia from healthy controls. <i>Psychiatry Research</i> , 2020, 288, 112938.	3.3	45
17	Attention deficit hyperactivity disorder: Last in, first out - delayed brain maturation with an accelerated decline?. <i>European Neuropsychopharmacology</i> , 2020, 34, 65-75.	0.7	9
18	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.7	60

#	ARTICLE	IF	CITATIONS
19	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019, 29, 971-985.	0.7	93
20	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
21	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1917-1924.	5.4	24
22	ADHD: a hidden comorbidity in adult psychiatric patients. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2019, 11, 83-89.	1.7	19
23	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. <i>European Psychiatry</i> , 2019, 56, 14-34.	0.2	330
24	Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 429-437.	3.2	41
25	Decreased resting gamma activity in adult attention deficit/hyperactivity disorder. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 691-702.	2.6	18
26	A systematic review of health economic models and utility estimation methods in schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 267-275.	1.4	32
27	A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). <i>European Neuropsychopharmacology</i> , 2018, 28, 185-194.	0.7	9
28	Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. <i>Comprehensive Psychiatry</i> , 2018, 85, 23-29.	3.1	8
29	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25â€“50â€“ mg/day) versus escitalopram (10â€“20â€“ mg/day) in out-patients with severe generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 970-979.	0.7	25
30	The Options and Limitations of the Brain Fingerprinting Lie Detection Method in the Criminal Proceeding. <i>Magyar RendÅ©szet</i> , 2018, 18, 43-56.	0.1	0
31	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	2.4	4
32	A proposal for a psychopharmacologyâ€“pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	2.6	13
33	Electrophysiological indices of aberrant error-processing in adults with ADHD: a new region of interest. <i>Brain Imaging and Behavior</i> , 2017, 11, 1616-1628.	2.1	12
34	Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. <i>Lancet</i> , 2017, 389, 1103-1113.	13.7	249
35	A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe. <i>Lancet Psychiatry</i> , 2017, 4, 634-642.	7.4	112
36	Neural Correlates of Error Monitoring in Adult Attention Deficit Hyperactivity Disorder After Failed Inhibition in an Emotional Go/No-Go Task. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 326-333.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Potential Role of Patients's CYP3A-Status in Clozapine Pharmacokinetics. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 529-537.	2.1	32
38	Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. <i>European Psychiatry</i> , 2017, 45, 97-103.	0.2	50
39	Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1043-1053.	1.8	22
40	Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw083.	2.1	23
41	Altered response-preparation in patients with adult ADHD: A high-density ERP study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 57-66.	1.8	8
42	Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. <i>JMIR MHealth and UHealth</i> , 2016, 4, e112.	3.7	23
43	Mental health research priorities for Europe. <i>Lancet Psychiatry</i> , 2015, 2, 1036-1042.	7.4	158
44	Treatment adherence and insight in schizophrenia. <i>Psychiatria Hungarica</i> , 2015, 30, 18-26.	0.2	15
45	ROAMER: roadmap for mental health research in Europe. <i>International Journal of Methods in Psychiatric Research</i> , 2014, 23, 1-14.	2.1	109
46	Common variant at 16p11.2 conferring risk of psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 108-114.	7.9	85
47	Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. <i>Schizophrenia Research</i> , 2014, 152, 246-254.	2.0	59
48	Stratified medicine for mental disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, 5-50.	0.7	152
49	Fearful face recognition in schizophrenia: An electrophysiological study. <i>Schizophrenia Research</i> , 2013, 149, 135-140.	2.0	21
50	Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. <i>BMC Psychiatry</i> , 2013, 13, 71.	2.6	15
51	Is ADHD severity in adults associated with the lifetime prevalence of comorbid depressive episodes and anxiety disorders?. <i>European Psychiatry</i> , 2013, 28, 308-314.	0.2	24
52	Genes and environments in schizophrenia: The different pieces of a manifold puzzle. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2424-2437.	6.1	44
53	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.7	137
54	Functional impairment in adults positively screened for attention-deficit hyperactivity disorder: The role of symptom presentation and executive functioning. <i>Comprehensive Psychiatry</i> , 2013, 54, 974-981.	3.1	20

#	ARTICLE	IF	CITATIONS
55	Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. <i>European Neuropsychopharmacology</i> , 2013, 23, 1383-1390.	0.7	29
56	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 258-261.	1.4	14
57	Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary. <i>Neuropsychopharmacologia Hungarica</i> , 2013, 15, 223-31.	0.1	11
58	Pharmacological treatment of adult ADHD. <i>Current Opinion in Psychiatry</i> , 2012, 25, 529-534.	6.3	15
59	State of psychiatry in Hungary. <i>International Review of Psychiatry</i> , 2012, 24, 307-313.	2.8	14
60	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. <i>European Psychiatry</i> , 2012, 27, 114-128.	0.2	39
61	Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder. <i>Biological Psychiatry</i> , 2012, 72, 645-650.	1.3	15
62	Drug Effect Prediction by Polypharmacology-Based Interaction Profiling. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 134-145.	5.4	57
63	The birth of convulsive therapy revisited: A reappraisal of László Meduna's first cohort of patients. <i>Journal of Affective Disorders</i> , 2012, 136, 1179-1182.	4.1	9
64	General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 107-115.	3.2	39
65	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , 2011, 20, 4076-4081.	2.9	193
66	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011, 43, 969-976.	21.4	1,758
67	Adverse reactions to duloxetine in depression. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 839-850.	2.4	24
68	Expanding the range of ZNF804A variants conferring risk of psychosis. <i>Molecular Psychiatry</i> , 2011, 16, 59-66.	7.9	140
69	P300 deficits in adults with attention deficit hyperactivity disorder: a meta-analysis. <i>Psychological Medicine</i> , 2011, 41, 1529-1538.	4.5	101
70	Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST). <i>Journal of Clinical Psychiatry</i> , 2011, 72, 955-961.	2.2	43
71	Association study of <i>NRG1</i> , <i>DTNBP1</i> , <i>RGS4</i> , <i>G72/G30</i> , and <i>PIP5K2A</i> with schizophrenia and symptom severity in a Hungarian sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 792-801.	1.7	37
72	How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 287-296.	3.2	46

#	ARTICLE	IF	CITATIONS
73	Relating the shape of protein binding sites to binding affinity profiles: is there an association?. BMC Structural Biology, 2010, 10, 32.	2.3	13
74	Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World Journal of Biological Psychiatry, 2010, 11, 894-903.	2.6	28
75	Executive function in deficit schizophrenia: What do the dimensions of the Wisconsin Card Sorting Test tell us?. Schizophrenia Research, 2010, 122, 85-93.	2.0	53
76	Deinstitutionalization in Europe: two recent examples from Germany and Hungary. Psychiatria Danubina, 2010, 22, 406-12.	0.4	6
77	Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychological Medicine, 2009, 39, 1337-1345.	4.5	122
78	Common variants conferring risk of schizophrenia. Nature, 2009, 460, 744-747.	27.8	1,572
79	Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. British Journal of Psychiatry, 2009, 194, 204-211.	2.8	1,200
80	Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. International Journal of Neuropsychopharmacology, 2009, 12, 1137.	2.1	114
81	László Meduna's Pilot Studies With Camphor Inductions of Seizures. Journal of ECT, 2009, 25, 3-11.	0.6	27
82	Convulsive therapy turns 75. British Journal of Psychiatry, 2009, 194, 387-388.	2.8	9
83	The beginnings of modern psychiatric treatment in Europe. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 434-440.	3.2	11
84	How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophrenia Research, 2008, 99, 200-207.	2.0	34
85	Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. European Neuropsychopharmacology, 2008, 18, 170-180.	0.7	22
86	Károly Schaffer and his school: The birth of biological psychiatry in Hungary, 1890-1940. European Psychiatry, 2008, 23, 449-456.	0.2	9
87	Associative learning in deficit and nondeficit schizophrenia. NeuroReport, 2008, 19, 55-58.	1.2	34
88	How well do patients with schizophrenia track multiple moving targets?. Neuropsychology, 2007, 21, 319-325.	1.3	7
89	Regressive and Intensive Methods of Electroconvulsive Therapy. Journal of ECT, 2007, 23, 229-232.	0.6	7
90	Validity of Reliability. Journal of Nervous and Mental Disease, 2007, 195, 606-613.	1.0	5

#	ARTICLE	IF	CITATIONS
91	A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. <i>European Psychiatry</i> , 2006, 21, 1-9.	0.2	13
92	Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. <i>Schizophrenia Research</i> , 2006, 81, 139-143.	2.0	23
93	Structural Analogues of Clozapine. , 2006, , 297-313.		3
94	Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 223-231.	4.5	26
95	Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 78-90.	2.4	4
96	Eficacia de la monoterapia de clozapina, olanzapina, quetiapina, risperidona y haloperidol en la reducción del comportamiento hostil y agresivo en pacientes ambulatorios tratados por esquizofrenia: un estudio naturalista prospectivo (IC-SOHO). <i>European Psychiatry (Ed Española)</i> , 2006, 13, 70-76.	0.0	0
97	Atropine Coma. <i>Journal of ECT</i> , 2005, 21, 203-206.	0.6	2
98	Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. <i>International Clinical Psychopharmacology</i> , 2005, 20, 19-21.	1.7	55
99	Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). <i>European Psychiatry</i> , 2005, 20, 403-408.	0.2	47
100	Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 173-180.	4.8	114
101	Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. <i>Current Therapeutic Research</i> , 2004, 65, 57-69.	1.2	1
102	Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. <i>European Neuropsychopharmacology</i> , 2004, 14, 457-470.	0.7	245
103	Effectiveness of Antipsychotic Treatments for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 312-321.	2.2	73
104	Prevalence and comorbidity of affective disorders in persons making suicide attempts in Hungary: importance of the first depressive episodes and of bipolar II diagnoses. <i>Journal of Affective Disorders</i> , 2003, 76, 113-119.	4.1	64
105	Prescribing for Inpatients with Schizophrenia: An International Multi-Center Comparative Study. <i>Pharmacopsychiatry</i> , 2003, 36, 143-149.	3.3	44
106	Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 716-721.	1.9	49
107	Prevalence of subthreshold forms of psychiatric disorders in persons making suicide attempts in Hungary. <i>European Psychiatry</i> , 2000, 15, 354-361.	0.2	25
108	Haloperidol Blood Levels and Clinical Effects. <i>Archives of General Psychiatry</i> , 1992, 49, 354.	12.3	114

#	ARTICLE	IF	CITATIONS
109	Relationship between the brief psychiatric rating scale and the scale for the assessment of negative symptoms: A study of their correlation and redundancy. <i>Psychiatry Research</i> , 1991, 36, 129-139.	3.3	40
110	Rhythmic movements of chronic akathisia. <i>Biological Psychiatry</i> , 1990, 27, 465-466.	1.3	0
111	The measurement of subjective experience in schizophrenia: The subjective deficit syndrome scale. <i>Comprehensive Psychiatry</i> , 1990, 31, 216-226.	3.1	63
112	Electrodermally differentiated subgroups of anxiety patients. I. Automatic and vigilance characteristics. <i>International Journal of Psychophysiology</i> , 1987, 5, 43-51.	1.0	17
113	Types of Complaints in Psychiatric and Internal Medical Patients. <i>Psychopathology</i> , 1985, 18, 241-253.	1.5	6
114	?-ENDORPHIN ADMINISTRATION TO ACUTE SCHIZOPHRENIC PATIENTS: A DOUBLE BLIND STUDY. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 460-469.	3.8	4